AD/PD™ 2024: Advances in Science & Therapy

Lisbon, Portugal and Online

The port city of Lisbon, the launch point of many a voyage of exploration, seemed a fitting site to host the 18th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders. Disease-modifying therapies for amyloid plaques now approved, researchers are searching for similar treatments for tau, synuclein, and other potential drivers of neurodegeneration. With more than 4,700 attendees navigating 600+ presentations during five days, often spread across six parallel sessions, the conference was bustling, yet imbued with a sense of discovery. Speakers discussed new small-molecule and antibody therapies, combination approaches, new plasma biomarkers for tau and TDP43, and a good smattering of basic biology, from cellular resilience to microglial diversity. Follow along with Alzforum’s conference coverage.

  1. Rubbing Microglia the Right Way? At ADPD, Scientists Showcase New Strategies
  2. Over the Span of AD, Roles of Astrocytes and Microglia Change
  3. Could Sumoylation Take Down Tangles?

Holloway Summit 2023: FTD Biomarkers

Miami Beach, Florida

To enable clinical trials in frontotemporal dementia, scientists need biomarkers that distinguish its several underlying pathologies. At a recent conference in Miami, speakers showed data on potential fluid biomarkers and PET tracers that could differentiate the two main proteinopathies, tau and TDP-43. They also discussed nascent markers and debuted an AI algorithm that improves the diagnostic capabilities of FDG-PET scans.

View all 2 articles on this conference

Clinical Trials on Alzheimer's Disease (CTAD) 2023 - 16th

Boston, Massachusetts

The 16th iteration of the Clinical Trials in Alzheimer’s Disease conference, held October 24-27 in Boston, drew some 2,300 participants, of whom 1,500 crowded into a downtown hotel for the in-person experience while 800 followed proceedings remotely. The meeting started with a session on how efforts to diversify research participation in trials are beginning to yield data on biomarker positivity among different groups, and continued with a focus on which patients might benefit most from amyloid reduction. 

View all 12 articles on this conference

2nd Symposium on Lipids in Brain Diseases

Leiden, Netherlands

The average human brain contains nearly a kilogram of fat. That’s right. The seat of your consciousness—that very thing that might be registering surprise right now—comprises about 60 percent lipid. What does it all do and how might it figure into Alzheimer’s and other neurodegenerative disorders? Scientists who gathered for the 2nd Symposium on Lipids in Brain Disease, shared some answers. From fats that drive proteinopathies and inflammation to others that might bring relief, learn about some of the newest concepts in Tom Fagan’s meeting series. 

View all 4 articles on this conference